Assura PLC Scrip dividend declaration (9325M)

TIDMAGR

RNS Number : 9325M

Assura PLC

14 January 2019

14 January 2019

Assura plc

Scrip Dividend Declaration

Assura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that, pursuant to its Scrip Dividend Scheme and in response to the scrip dividend alternative for the quarterly interim dividend payable on 16 January 2019 (the "Scrip Dividend Alternative"), elections were received in respect of 14 per cent. of the Company's ordinary shares in issue as at the record date of 14 December 2019.

Electing shareholders will receive ordinary shares in the Company ("Shares") in lieu of cash in respect of this dividend and, accordingly 4,195,055 Shares (the "New Shares") will be issued by the Company to such shareholders.

Application has therefore been made for the admission of the New Shares to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities ("Admission"). The New Shares will rank pari passu with the Company's existing ordinary shares and Admission is expected to occur at 8.00am on 16 January 2019.

Following the allotment of the New Shares, it is expected that the total number of shares in issue will be 2,398,085,921 (none of which will be held in treasury) and that, accordingly, the total number of voting rights of the Company will be 2,398,085,921.

Copies of the documents relating to the Scrip Dividend Alternative are available for inspection through the National Storage Mechanism (http://www.morningstar.co.uk/uk/NSM).

This interim dividend is 100% ordinary dividend (non-PID).

Forms to register for gross PIDs (on future interim dividends) are available on the Company's website. Please click here for PID Forms.

-ENDS-

For more information, please contact:

 
 
    Assura plc      Tel: [phone] 
  Orla Ball 
   David Purcell 
 
    Edelman         Tel: [phone] 
  John Kiely 
   Rob Yates 
 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. At 30 September 2018, Assura's property portfolio was valued at GBP1,843 million.

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association

Assura plc LEI code: 21380026T19N2Y52XF72

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DIVGMGMMNMLGLZM

(END) Dow Jones Newswires

January 14, 2019 02:00 ET (07:00 GMT)